A randomized, double blind, balanced, single center, two treatment, two period, two sequence, single dose, crossover relative bioavailability study of turmeric extracts in healthy human adult subjects, under fasting conditions.

Exodus Research Acer0 个研究点目标入组 16 人开始时间: 待定最近更新: 2021年11月24日

试验速览

阶段: 未知
状态: 已完成
发起方
入组人数: 16

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Ba/be

入排标准

入选标准

•a.Be healthy male or non-pregnant and non-lactating female 18 to 45 years of age, both ages inclusive.
•b.Be healthy male or non-pregnant and non-lactating female of BMI within 18.50 to 24.99 Kg/ m2. Volunteers weighing less than 50 kg will not be enrolled.
•c.Be able to communicate effectively with the study personnel.
•d.Be a non consumer (user) of tobacco (not consumed tobacco in the past 6 months) or a mild or moderate consumer (user) of tobacco.
•e.Have no evidence of underlying disease during screening medical history and whose physical examination is performed within 21 days prior to check in of period one.
•f.Be medically healthy with clinically acceptable laboratory profiles, ECG (performed within 21 days prior to check-in of period one) and chest X-ray (performed within 6 months prior to check-in of period one).
•g.Have given the written informed consent for voluntary participation in the study.
•h.Be declared eligible to participate in the study by the investigator(s).
•i.In addition, female volunteers selected for the study must:
•i)Be using a medically acceptable form of birth control (such as foams, jellies, diaphragm, intra-uterine device (IUD) or abstinence) for the duration of the study as judged by the investigator(s) Or
•ii)Be sterilized by surgical methods (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy) at least 6 months back Or
•iii)Have attained menopause at least 1 year back.
•iv)And have a negative urine pregnancy test prior to check-in to the clinical facility.

排除标准

•a.Participation in any bioavailability, bioequivalence, Pharmacokinetic study or received an investigational drug within a period of 3 months prior to check in of period one.
•b.History of drug abuse, or alcohol dependence or abuse.
•c.History of any allergies (asthma, urticaria) including drug allergies.
•d.Known hypersensitivity or allergy to curcuminoids or any of the excipients or related drugs
•e.Severe consumer of tobacco.
•f.Presence of a clinically significant disorder involving the cardiovascular,respiratory, renal, gastrointestinal, hepatic, immunologic, hematological, endocrine, or nervous system or psychiatric disease or other conditions that may interfere with the absorption, distribution, metabolism or excretion of study drug, or would place the subject at increased risk, as determined by the investigator.
•g.Volunteers who have,
•i.Systolic blood pressure less than 90 mm of Hg or more than 140 mm of Hg. Diastolic blood pressure less than 60 mm of Hg or more than 90 mm of Hg. Minor deviations 2-4 mm of Hg at check-in may be acceptable at the discretion of the physician /investigator.
•ii.Pulse rate below 60 per minute or above 100 per minute.
•iii.Respiratory rate below 15 or above 20 breaths per minute.
•iv.Oral temperature less than 96.2F or more than 99.8F.
•h.Clinical laboratory test values outside the acceptable reference range and when confirmed on re-examination deemed to be clinically significant.
•i.Positive screening results for Hepatitis B, Hepatitis C, HIV or Syphilis.
•j.Subject who has donated blood in the preceding 12 weeks prior to the check in of period one.
•k.Already taking a nutritional supplement containing turmeric extracts and unable to discontinue using it 7 days prior to dosing.
•l.Clinically significant illness during the 4 weeks prior to check-in of period one as determined by the investigators.
•m.Use of any prescription drug for systemic action in the 28 days prior to check-in of period one or OTC, herbal medications drug 14 days prior to check-in of period one.
•n.Positive result in breath analysis test for alcohol.
•o.Positive urine drug screening results for any of the following: cocaine, THC, barbiturates, amphetamines, benzodiazepines, and morphine.
•p.History of difficulty in swallowing tablets or capsules.
•q.Positive test for pregnancy for female subjects.

研究者

发起方

Exodus Research Acer

相似试验

进行中（未招募）

不适用

This study is designed to evaluate and compare the ease of swallowing and palatability (roughness, stickiness, slipperiness, and taste), of specialized coating(easyglide) vs conventional (Opadry) coating and uncoated placebo tablets in healthy adult volunteers.

CTRI/2020/11/029406Abbott Healthcare Pvt Ltd

已完成

3 期

To evaluate effect of KSM-66 Ashwagandha® Capsule (300 mg) in Management of Frailty in Older Adults

CTRI/2022/02/040554Ixoreal Biomed50

进行中（未招募）

1 期

A clinical trial testing usual dose and double dose oseltamivir (the medicine) in which neither the doctor or patient know what dose of medicine is given for treatment of influenza (the flu), in patients with a weakened immune (protective) system.To investigate the optimal therapy for influenza in immunocompromised patients.MedDRA version: 17.1Level: PTClassification code 10022000Term: InfluenzaSystem Organ Class: 10021881 - Infections and infestations

EUCTR2006-002468-24-HUF.Hoffmann-La Roche Ltd.166

进行中（未招募）

1 期

EUCTR2006-002468-24-BGF.Hoffmann-La Roche Ltd.228

进行中（未招募）

1 期

A clinical trial testing usual dose and double dose oseltamivir (the medicine) in which neither the doctor or patient know what dose of medicine is given for treatment of influenza (the flu), in patients with a weakened immune (protective) system.To investigate the optimal therapy for influenza in immunocompromised patients.MedDRA version: 19.1 Level: PT Classification code 10022000 Term: Influenza System Organ Class: 10021881 - Infections and infestations

EUCTR2006-002468-24-DEF.Hoffmann-La Roche Ltd.215